Elsevier

Lung Cancer

Volume 49, Issue 2, August 2005, Pages 217-223
Lung Cancer

Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy

https://doi.org/10.1016/j.lungcan.2005.01.008Get rights and content

Summary

Background:

The efficacy of chemotherapy in patients with large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear.

Methods:

Patients with LCNEC who received cisplatin-based chemotherapy were identified by reviewing 567 autopsied and 2790 surgically resected lung cancer patients. The clinical characteristics and objective responses to chemotherapy in these patients were analyzed.

Results:

Overall, 20 cases of LCNEC were identified, including stage IIIA (n = 3), stage IIIB (n = 6), stage IV (n = 6) and postoperative recurrence (n = 5) cases. Six patients had received prior chemotherapy, and 14 were chemo-naive patients. The patients had received a combination of cisplatin and etoposide (n = 9), cisplatin, vindesine and mitomycin (n = 6), cisplatin and vindesine (n = 4), or cisplatin alone (n = 1). One patient showed complete response and nine showed partial response, yielding an objective response rate of 50%. The response rate did not differ between patients with the initial diagnosis of SCLC and those with the initial diagnosis of NSCLC, however, the response rate in chemo-naive patients (64%) was significantly different from that in previously treated patients (17%).

Conclusions:

Our results suggest that the response rate of LCNEC to cisplatin-based chemotherapy was comparable to that of SCLC.

Introduction

Pulmonary neuroendocrine tumors include a spectrum of four clinicopathological entities classified on the basis of the morphological and biological features: typical carcionoid and atypical carcinoid, which are tumors of low to intermediate grade malignancy, and large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCLC), which are high-grade malignant tumors. Travis et al. proposed the term LCNEC in 1991 [1], for classifying a type of poorly differentiated high-grade carcinoma characterized by a neuroendocrine appearance under light microscopy. LCNEC exhibits more prominent cellular pleomorphism and higher mitotic activity than the atypical carcinoid (AC), and is distinguished from SCLC by the tumor cell size and chromatin morphology. Although several different terminologies and classifications have been proposed previously, and even the present classification of pulmonary neuroendocrine tumors lacks uniform definition criteria, this class of tumors could become widely accepted and included in the updated histological classification of the World Health Organization [2].

The clinical features of LCNEC have not yet been completely clarified. The prognosis of patients with surgically resected LCNEC is reported to be intermediate between that of AC and SCLC [3], [4], [5], and the same as that of resected NSCLC, except that stage I LCNEC has a poorer prognosis than stage I non-small cell lung cancer (NSCLC) [6]. To the best of our knowledge, however, there are no studies that have examined the role of chemotherapy for LCNEC and the prognosis of patients with unresectable LCNEC, even though several reports have been published on the association between response to chemotherapy and the neuroendocrine differentiation of NSCLC [7], [8], [9]. The appropriate treatment of unresectable LCNEC, therefore, remains unclear. In the present study, we attempted to investigate the effectiveness of chemotherapy with cisplatin-based regimens for LCNEC in patients with unresectable and recurrent LCNEC.

Section snippets

Materials and methods

Eighty-seven of 2790 patients with primary lung cancer who underwent tumor resection from 1982 to 1999 at the National Cancer Center Hospital were found to have tumors with the histological characteristics of LCNEC [6]. Of these, five had received cisplatin-based chemotherapy at the time of recurrence, and were enrolled as subjects of this study. In addition, 303 of 567 patients who were autopsied from 1983 to 1997 at the National Cancer Center Hospital who had the following histological

Results

Overall, 22 cases were recognized as having tumors with histological characteristics consistent with LCNEC among the autopsied and surgically resected cases of primary lung cancer that had received cisplatin-based chemotherapy and had evaluable lesions; of these 17 were autopsied cases and five were surgically resected cases. Two of the autopsied cases were excluded, because no pretreatment pathological or cytological samples were available. The typical microscopic appearance of the tumor

Discussion

In this extensive review of over 3000 lung cancer patients, we found considerable difficulty in evaluating the response of LCNEC to systemic chemotherapy. The pathological diagnosis of LCNEC was established in 87 (3.1%) of 2790 patients treated by surgical resection. This low incidence of LCNEC in surgically treated lung cancer patients is comparable to that in other previously published reports: 2.4% (50/2070), 2.9% (22/766), and 3.6% (53/1530) [16], [17], [18]. Of the 87 patients, only five

Acknowledgment

We thank Ms. Yuko Yabe for kindly preparing this manuscript.

References (22)

  • S.L. Graziano et al.

    The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer

    J Clin Oncol

    (1989)
  • Cited by (101)

    • Neuroendocrine neoplasms of the lung

      2022, Practical Pulmonary Pathology: A Diagnostic Approach
    • Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study

      2020, Lung Cancer
      Citation Excerpt :

      In the current study, 56 patients were available for the adjuvant cohort, and we found that SCLC-based regimens seemed to be the more effective than NSCLC-based regimens. This supports the results of other studies in this area, which have shown that an SCLC regimen is the better first-line chemotherapy [8,10,18,19]. On the other hand, in this study, there were still 87 patients (59.6 %) in the first-line cohort, and 43 patients (76.8 %) in the adjuvant cohort receiving an NSCLC regimen.

    View all citing articles on Scopus
    View full text